发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
38P Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma 38P生物标志物预测转移性黑色素瘤患者对免疫检查点抑制剂治疗的反应
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100920
E.M. Bob , C.C. Burz
{"title":"38P Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma","authors":"E.M. Bob , C.C. Burz","doi":"10.1016/j.iotech.2024.100920","DOIUrl":"10.1016/j.iotech.2024.100920","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100920"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
82P Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count 82P生物标志物对局部晚期肿瘤患者新辅助免疫化疗疗效的预测：基于肿瘤收缩率和淋巴细胞计数变化的回顾性分析
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100825
Z. Zhang , K. Yang , S. Zhao , Z. Yang , Z. Xiong
{"title":"82P Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count","authors":"Z. Zhang , K. Yang , S. Zhao , Z. Yang , Z. Xiong","doi":"10.1016/j.iotech.2024.100825","DOIUrl":"10.1016/j.iotech.2024.100825","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100825"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
88P Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application 88P在世卫组织基本药物应用标准清单中优先考虑免疫检查点抑制剂时使用ESMO-MCBS
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100831
M. Csenar , J. Schroer , M. Goldkuhle , L. Moja , N. Skoetz
{"title":"88P Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application","authors":"M. Csenar , J. Schroer , M. Goldkuhle , L. Moja , N. Skoetz","doi":"10.1016/j.iotech.2024.100831","DOIUrl":"10.1016/j.iotech.2024.100831","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100831"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
52P Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models 在小鼠模型中，通过基因工程骨髓细胞释放肿瘤靶向细胞因子挽救CAR-T活性，并参与内源性T细胞对抗高级别胶质瘤
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100863
F. Rossari , G. Alvisi , M. Cusimano , S. Beretta , F. Birocchi , D. Ambrosecchia , O. Vitaloni , C. Brombin , P.M.V. Rancoita , T. Canu , G. Orofino , A. Annoni , B. Gentner , M.L. Squadrito , M. Genua , R. Ostuni , I. Merelli , N. Coltella , L. Naldini
{"title":"52P Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models","authors":"F. Rossari , G. Alvisi , M. Cusimano , S. Beretta , F. Birocchi , D. Ambrosecchia , O. Vitaloni , C. Brombin , P.M.V. Rancoita , T. Canu , G. Orofino , A. Annoni , B. Gentner , M.L. Squadrito , M. Genua , R. Ostuni , I. Merelli , N. Coltella , L. Naldini","doi":"10.1016/j.iotech.2024.100863","DOIUrl":"10.1016/j.iotech.2024.100863","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100863"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143130225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
17P Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer pd - l1相关lncRNA生物标志物在卵巢癌免疫调节中的鉴定
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100900
H.J. Kim , B.K. Jung , L.K. Kim , S-A. Park , T-H. Heo
{"title":"17P Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer","authors":"H.J. Kim , B.K. Jung , L.K. Kim , S-A. Park , T-H. Heo","doi":"10.1016/j.iotech.2024.100900","DOIUrl":"10.1016/j.iotech.2024.100900","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100900"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy 接受免疫治疗的患者AXL和/或MITF黑色素瘤亚群的变化
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.101009
M. Willemsen , J. Bulgarelli , S.K. Chauhan , R.R. Lereim , D. Angeli , G. Grisendi , G. Krebbers , I. Davidson , J.A. Kyte , M. Guidoboni , R.M. Luiten , W.J. Bakker
{"title":"Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy","authors":"M. Willemsen ,&nbsp;J. Bulgarelli ,&nbsp;S.K. Chauhan ,&nbsp;R.R. Lereim ,&nbsp;D. Angeli ,&nbsp;G. Grisendi ,&nbsp;G. Krebbers ,&nbsp;I. Davidson ,&nbsp;J.A. Kyte ,&nbsp;M. Guidoboni ,&nbsp;R.M. Luiten ,&nbsp;W.J. Bakker","doi":"10.1016/j.iotech.2024.101009","DOIUrl":"10.1016/j.iotech.2024.101009","url":null,"abstract":"<div><h3>Background</h3><div>Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the ‘mixed responses’ frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respond to RAF and MEK inhibitors.</div></div><div><h3>Patients and methods</h3><div>In this study, we analyzed tumor heterogeneity and explored the presence of the previously described AXL+ or MITF+ melanoma subpopulations in metastatic tissues by NanoString gene expression analysis, single-cell RNA sequencing and <em>in situ</em> multiplex immunofluorescence. Furthermore, we analyzed how these subpopulations correlate with immunological pressure and response to immunotherapy by immunomodulating antibodies or autologous tumor lysate-loaded dendritic cell vaccination.</div></div><div><h3>Results</h3><div>Our data demonstrate large interpatient variability and variable therapy-induced changes independent of the type of therapy. We identify the presence of previously described AXL+ and MITF+ subpopulations in metastatic tissues both at the mRNA level and <em>in situ</em> at the protein level, and demonstrate that MITF+ melanoma cells are significantly decreased upon immunotherapy, while AXL+ melanoma cell numbers are stable. MITF+ tumor cells showed the most significant inverse correlation with CD8+ T cells. Our patient cohort also shows that immunotherapy-induced changes in the abundance of AXL+ or MITF+ tumor cells did not correlate with improved survival.</div></div><div><h3>Conclusions</h3><div>Overall, this study suggests that more differentiated MITF+ tumors are efficiently targeted by immunotherapy, while AXL+ tumor cells may be more resistant, analogous to their response to targeted therapy.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101009"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
29P Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial 29P: AURA试验中肌肉侵袭性膀胱癌患者接受新辅助化疗-免疫治疗的全身炎症指数和血小板/淋巴细胞比值的预后价值
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100911
J. Blanc , N. Martinez Chanza , A. Carnot , P. Barthelemy , N. Kotecki , M. Maetens , G. Dosin , A.H. Awada , D. Venet , C. Sotiriou , S. Rorive , F. Rothé
{"title":"29P Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial","authors":"J. Blanc ,&nbsp;N. Martinez Chanza ,&nbsp;A. Carnot ,&nbsp;P. Barthelemy ,&nbsp;N. Kotecki ,&nbsp;M. Maetens ,&nbsp;G. Dosin ,&nbsp;A.H. Awada ,&nbsp;D. Venet ,&nbsp;C. Sotiriou ,&nbsp;S. Rorive ,&nbsp;F. Rothé","doi":"10.1016/j.iotech.2024.100911","DOIUrl":"10.1016/j.iotech.2024.100911","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100911"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
55P Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment 嵌合细胞因子受体（CCR）的55P工程诱导IL-7信号传导至CAR-T细胞用于实体瘤治疗
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100866
M. Soria-Castellano, S. Colell, T. Lobo-Jarne, C.A. Di Trani, M. Giménez-Alejandre, P. Barbao, I. Andreu-Saumell, H. Calderon, J. Castellsagué, A. Rodriguez Garcia, S. Guedan
{"title":"55P Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment","authors":"M. Soria-Castellano,&nbsp;S. Colell,&nbsp;T. Lobo-Jarne,&nbsp;C.A. Di Trani,&nbsp;M. Giménez-Alejandre,&nbsp;P. Barbao,&nbsp;I. Andreu-Saumell,&nbsp;H. Calderon,&nbsp;J. Castellsagué,&nbsp;A. Rodriguez Garcia,&nbsp;S. Guedan","doi":"10.1016/j.iotech.2024.100866","DOIUrl":"10.1016/j.iotech.2024.100866","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100866"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
80P Tumor markers evolution in pts treated with TCE and association with radiologic response 80P: TCE治疗患者肿瘤标志物的演变及其与放射学反应的关系
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100823
C. d'Abrigeon , K. Ouali , N. Herbel , S. Champiat , A. Hollebecque , C. Smolenschi , M. Sakkal , R. Bahleda , A. Gazzah , A. Patrikidou , J-M. Michot , T. Hueso , S. Ammari , Y. Loriot , C.P. Massard , A. Bernard-Tessier , M. Texier , C. Baldini
{"title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","authors":"C. d'Abrigeon ,&nbsp;K. Ouali ,&nbsp;N. Herbel ,&nbsp;S. Champiat ,&nbsp;A. Hollebecque ,&nbsp;C. Smolenschi ,&nbsp;M. Sakkal ,&nbsp;R. Bahleda ,&nbsp;A. Gazzah ,&nbsp;A. Patrikidou ,&nbsp;J-M. Michot ,&nbsp;T. Hueso ,&nbsp;S. Ammari ,&nbsp;Y. Loriot ,&nbsp;C.P. Massard ,&nbsp;A. Bernard-Tessier ,&nbsp;M. Texier ,&nbsp;C. Baldini","doi":"10.1016/j.iotech.2024.100823","DOIUrl":"10.1016/j.iotech.2024.100823","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100823"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3MO LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma 3MO LDH亚型塑造了转移性黑色素瘤的免疫微环境并影响治疗反应和生存
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100887
L. Soumoy , V. Quidville , C. Sarre-Pradon , L. Lacroix , E. Routier , H. Hermann , S. Roy , N. Benannoune , S. Vagner , F. Chehade , B. Archambaud , C. Robert
{"title":"3MO LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma","authors":"L. Soumoy ,&nbsp;V. Quidville ,&nbsp;C. Sarre-Pradon ,&nbsp;L. Lacroix ,&nbsp;E. Routier ,&nbsp;H. Hermann ,&nbsp;S. Roy ,&nbsp;N. Benannoune ,&nbsp;S. Vagner ,&nbsp;F. Chehade ,&nbsp;B. Archambaud ,&nbsp;C. Robert","doi":"10.1016/j.iotech.2024.100887","DOIUrl":"10.1016/j.iotech.2024.100887","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100887"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信